iSpecimen will supply the U.S. Centers for Disease Control and Prevention (CDC) with serum samples from subjects who have previously tested positive for SARS-CoV-2, the virus that causes COVID-19.
Researchers are having a hard time getting their hands on specimens for their work on new treatments, diagnostics, and cures.
Before there are new therapies to set a firm apart, there is a far more fundamental need that competitiveness will ultimately hinge on: high-quality, diversified, annotated human biospecimens.
